Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
14/10/2026 15:36
BRIEF-Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026 Oct 14 (Reuters) - Oncolytics Biotech Inc ONCY.O:
ONCOLYTICS BIOTECH® PROVIDES UPDATE ON GOBLET STUDY CLINICAL DATA AND FINAL PANCAN GRANT PAYMENT
ONCOLYTICS BIOTECH - FINAL COHORT 4 RESULTS EXPECTED IN Q4 2026; INITIAL COHORT 5 RESULTS IN H1 2027
ONCOLYTICS BIOTECH - TO RECEIVE FINAL PANCAN GRANT PAYMENT LATER THIS QUARTER
Source text: ID:nGNX65TSFL
Further company coverage: ONCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
Brief: Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process
Brief: Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer